Andrew Callos - Cytokinetics Executive Officer
| CYTK Stock | USD 49.97 1.32 2.71% |
Executive
Andrew Callos is Executive Officer of Cytokinetics
| Age | 56 |
| Phone | 650 624 3000 |
| Web | https://www.cytokinetics.com |
Andrew Callos Latest Insider Activity
Tracking and analyzing the buying and selling activities of Andrew Callos against Cytokinetics stock is an integral part of due diligence when investing in Cytokinetics. Andrew Callos insider activity provides valuable insight into whether Cytokinetics is net buyers or sellers over its current business cycle. Note, Cytokinetics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Cytokinetics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Andrew Callos over six months ago Acquisition by Andrew Callos of 16941 shares of Cytokinetics subject to Rule 16b-3 | ||
Andrew Callos over six months ago Disposition of 5103 shares by Andrew Callos of Cytokinetics at 66.88 subject to Rule 16b-3 |
Cytokinetics Management Efficiency
The company has return on total asset (ROA) of (0.3013) % which means that it has lost $0.3013 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.7215) %, meaning that it created substantial loss on money invested by shareholders. Cytokinetics' management efficiency ratios could be used to measure how well Cytokinetics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jeff Boyle | Arvinas | N/A | |
| Peter Rahmer | Relay Therapeutics | N/A | |
| Keith White | Amylyx Pharmaceuticals | N/A | |
| Randy Teel | Arvinas | 45 | |
| Debra DursoBumpus | Blueprint Medicines Corp | 55 | |
| Tammy Sarnelli | Amylyx Pharmaceuticals | N/A | |
| Diana Chung | Terns Pharmaceuticals | N/A | |
| Robert MD | Edgewise Therapeutics | N/A | |
| Scott Harris | Terns Pharmaceuticals | N/A | |
| Delphine Imbert | Pliant Therapeutics | N/A | |
| Kathryn Haviland | Blueprint Medicines Corp | 48 | |
| Christopher Keenan | Pliant Therapeutics | N/A | |
| Christina Rossi | Blueprint Medicines Corp | 47 | |
| Debra Sieminski | Terns Pharmaceuticals | N/A | |
| Daniel Wilson | Dyne Therapeutics | 53 | |
| Soojin Kim | Inozyme Pharma | N/A | |
| John MBA | Dyne Therapeutics | 62 | |
| Johanna FriedlNaderer | Dyne Therapeutics | 57 | |
| Mark MBA | X4 Pharmaceuticals | 61 | |
| Lindsey Allen | Amylyx Pharmaceuticals | N/A | |
| John Grosso | Arvinas | 67 | |
Management Performance
| Return On Equity | -5.72 | ||||
| Return On Asset | -0.3 |
Cytokinetics Leadership Team
Elected by the shareholders, the Cytokinetics' board of directors comprises two types of representatives: Cytokinetics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cytokinetics. The board's role is to monitor Cytokinetics' management team and ensure that shareholders' interests are well served. Cytokinetics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cytokinetics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andrew Callos, Executive Officer | ||
| Jeff Lotz, Vice Operations | ||
| Robert Wong, Chief Accounting Officer, Vice President | ||
| Steven Cook, Senior Operations | ||
| Sung Lee, Executive CFO | ||
| Scott Jordan, Senior Strategy | ||
| John Esq, Associate VP | ||
| FACC MD, Ex RD | ||
| Eric Terhaerdt, Senior Operations | ||
| YulyMae DiNapoli, Vice Resources | ||
| Matt Yang, Vice Analysis | ||
| Steven JD, Senior Operations | ||
| James Spudich, CoFounder Board | ||
| Joanna Siegall, Associate Relations | ||
| Stuart MD, Senior Officer | ||
| Ching Jaw, CFO, Senior Vice President | ||
| Robert Blum, CEO and President Director and Chief Executive of the Biopharmaceutical Concern | ||
| Kari JD, VP Officer | ||
| Diane Weiser, IR Contact Officer |
Cytokinetics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cytokinetics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -5.72 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (304.11) % | ||||
| Current Valuation | 5.52 B | ||||
| Shares Outstanding | 118.01 M | ||||
| Shares Owned By Insiders | 0.53 % | ||||
| Shares Owned By Institutions | 99.47 % | ||||
| Number Of Shares Shorted | 14.03 M | ||||
| Price To Earning | (37.76) X | ||||
| Price To Book | 60.31 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytokinetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytokinetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.